Trials have demonstrated the possible beneficial role of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) in the AKI population, which might reduce mortality [20,21,22]. The gene discussed is ACE; the disease is acute kidney injury.